Background
==========

Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The presentation of COVID-19 includes dyspnea, lung edema, and pneumonia. Morbidity and mortality are associated with Acute Respiratory Distress Syndrome (ARDS) and cytokine storm. Hospitalized COVID-19 patients are classified as severe if they require intensive care unit (ICU) admission \[[@b1-amjcaserep-21-e926779],[@b2-amjcaserep-21-e926779]\]. Here, we report the first case of the use of supportive or adjunctive photobiomodulation therapy (PBMT) in a patient with severe COVID-19 pneumonia.

PBMT is an emerging alternative modality with demonstrated anti-inflammatory effects in pain management, lymphedema, wound healing, and musculoskeletal injuries. Additional terms for PBMT include low-level laser (or light) therapy (LLLT), cold laser, and photobiostimulation \[[@b3-amjcaserep-21-e926779]\]. The effects of PBMT differ from the thermal effects produced by the high-power lasers used in cosmetic and surgical procedures to destroy the tissue \[[@b4-amjcaserep-21-e926779],[@b5-amjcaserep-21-e926779]\]. PBMT utilizes non-ionizing, non-thermal light sources in the visible and infrared spectra (400--1000 nm) \[[@b3-amjcaserep-21-e926779]\]. In PBMT, light is applied over damaged tissues and the light energy absorbed by intracellular chromophores or biomolecules starts a cascade of molecular reactions that improve cell function and enhance the body's healing process \[[@b4-amjcaserep-21-e926779]\]. In effect, light stimulates healing, modulates the immune system, and reduces inflammation, edema, and pain \[[@b4-amjcaserep-21-e926779]\]. PBMT is non-invasive, cost-effective, and has no known adverse effects.

Empirical use of PBMT in children, adults, and elderly patients with pneumonia, asthma, chronic bronchitis, or pulmonary fibrosis resulted in reduced chest pain and heaviness, normalization of respiratory function, shortened recovery times, and improved immunological and radiological parameters. In these patients, PBMT used in combination with conventional medical treatment was safe and appeared to produce a synergistic effect in healing \[[@b6-amjcaserep-21-e926779]--[@b10-amjcaserep-21-e926779]\]. Recent publications recommend the use of supportive PBMT in COVID-19 patients \[[@b11-amjcaserep-21-e926779]--[@b13-amjcaserep-21-e926779]\]. ARDS is a critical complication of COVID-19 infection and supportive PBMT can ameliorate ARDS and promote lung healing \[[@b11-amjcaserep-21-e926779],[@b13-amjcaserep-21-e926779]--[@b18-amjcaserep-21-e926779]\]. Animal models of acute inflammation of the respiratory system suggest that transcutaneous PBMT over the lungs is effective against cytokine storm and ARDS via its anti-inflammatory action at multiple levels \[[@b14-amjcaserep-21-e926779]--[@b18-amjcaserep-21-e926779]\].

The theory of supportive PBMT for COVID-19 is based on laser light reaching lung tissue, which relieves inflammation and promotes healing. The World Association for Laser Therapy recommended treatment doses for low-level laser therapy, or PBMT for superficial to deep tissue lesions in musculoskeletal disorders in 2010 \[[@b19-amjcaserep-21-e926779]\].

The minimum observed therapeutic dose for a bio-stimulatory effect of red and near-infrared (NIR) lasers is 0.01 J/cm^2^ \[[@b20-amjcaserep-21-e926779]\]. NIR Laser light at a power of 1 W/cm^2^ projected through bovine tissue ranging in thickness from 1.8 to 9.5 cm resulted in effective power densities at 3.4 cm and 6.0 cm \[[@b21-amjcaserep-21-e926779]\]. In veterinary practice, feline and canine pneumonia is frequently treated with laser doses of 6--10 J/cm^2^ \[[@b22-amjcaserep-21-e926779]\]. These animals have a thicker chest wall and furry skin, making penetration more challenging than in humans. Therefore, the range used in cats and dogs approximates an effective dose for humans.

Our previous experience in treating asthma \[[@b23-amjcaserep-21-e926779]\] and musculo-skeletal pain and injuries suggested that the anti-inflammatory effects of PBMT could benefit the severe inflammatory condition in COVID-19 patients. The laser machine used in this case is an US Food and Drug Administration (FDA)-cleared system for pain management and inflammation reduction in deep joints of the body. The combination of 808 and 905 nm, both NIR wavelengths, provides penetration to depths of 4--5.4 cm. This laser machine is used for deeper tissues like hips and pelvic joints that are surrounded by thick muscles. The therapeutic dose with this machine is 4.5 J/cm^2^ over the skin to reach these deep targets of the pelvis. Based on our calculations, we used 7.2 J/cm^2^ over the skin to deliver just over 0.01 J/cm2 of laser energy to the lung. The 7.2 J/cm^2^ dosage penetrates the chest wall (1.6 to 6 cm in humans) and reaches the lung tissue with sufficient energy for bio-stimulation. Scapular protraction in the prone position reduces the bone and muscle tissue the laser must penetrate, thereby increasing laser energy to the lung fields.

Here, we report the first use of PBMT as a supportive treatment in a severe case of COVID-19 pneumonia.

Case Report
===========

A 57-year-old African American man with a history of hypertension and asthma presented with shortness of breath, severe dehydration, acute renal failure, and *C. difficile-*positive diarrhea. A physical examination revealed labored breathing, weakness, and fatigue. Chest X-rays demonstrated worsening bilateral lung infiltrates. Oxygen requirements in the hospital ranged from 2 to 6 L/min oxygen. The patient had been in the ICU for respiratory depression with SpO~2~ of 80% requiring 48 h on 6 L/min oxygen. The diagnosis of SARS-CoV-2 was confirmed for this patient by reverse transcription-polymerase chain reaction by nasopharyngeal swab on an Abbott ID system. Patient consent was obtained for an FDA-guided and International Review Board-approved trial of laser treatment for COVID-19 (Lowell General Hospital Federal-wide Assurance number 0001427). The inclusion criteria consisted of a positive COVID-19 test, the ability to self-prone, and requiring at least 1 L/min oxygen.

The patient was treated with an FDA-cleared Multiwave Locked System (MLS) Therapy Laser (ASA Laser, Italy.) The MLS laser utilizes a mobile scanner with 2 synchronized laser diodes, one in pulse mode (adjustable to 1--2000 Hz), emitting at 905 nm, and another in pulsed mode emitting at 808 nm. The 2 laser beams work simultaneously and synchronously. This laser is used in pain centers for treatment of musculoskeletal pain and inflammation. Laser parameters were set as outlined in [Table 1](#t1-amjcaserep-21-e926779){ref-type="table"} and [Figure 1](#f1-amjcaserep-21-e926779){ref-type="fig"}. The laser scanner was adjusted to 20 cm above the skin, as recommended by the manufacturer. Each lung was scanned for 14 min from apex to base over 250 cm^2^ of the posterior thorax ([Table 1](#t1-amjcaserep-21-e926779){ref-type="table"}, [Figures 1](#f1-amjcaserep-21-e926779){ref-type="fig"}, [2](#f2-amjcaserep-21-e926779){ref-type="fig"}).

Specific prone positioning was used with the patient's hands under his head for maximal scapular protraction. The laser field was focused to the medial border of the scapula opening the lung fields, thereby minimizing the chest wall thickness for theoretical improvement of laser penetration to lung tissue.

Prior to laser treatment, the patient was bedridden, with SpO~2~ 92--95% on 2--4 L/min oxygen. He had completed his antibiotic course and was not receiving any pharmacotherapeutic or IV support. He experienced severe paroxysmal coughing episodes and had failed a physical therapy trial. The patient tolerated the prone position for laser treatment for a total of 28 min. Within 5 min of laser treatment, his oxygen saturation rose from 94% to 100% in the first session. Following treatment, he returned to his bed and resumed the semi-sitting position and SpO~2~ remained at 98% for the rest of the day.

The patient tolerated all 4 daily treatments and noted significant improvement in breathing immediately after each treatment. Paroxysmal coughing spells resolved after the third treatment. Upon completion of the fourth treatment, the patient was able to ambulate in the room with physical therapy. On the day following his final treatment, the patient was discharged to an acute rehabilitation facility on 1 L/min oxygen. On the day after arrival to the acute rehabilitation facility, the patient was able to complete 2 trials of stair climbing with physical therapy and was in the process of weaning to room air.

The patient's response to PBMT was evaluated by comparing different scoring tools before and after laser therapy. The patient showed improvement in all evaluation criteria ([Table 2](#t2-amjcaserep-21-e926779){ref-type="table"}).

The Pneumonia Severity Index (PSI) \[[@b24-amjcaserep-21-e926779]\] calculates the probability of morbidity and mortality among patients with community-acquired pneumonia (CAP). Prior to treatment, the patient's PSI score was Class V (142), which requires ICU treatment and predicts intubation and ventilator use. After PBMT, PSI decreased to Class II (67), which signifies outpatient treatment.

The SMART-COP score \[[@b25-amjcaserep-21-e926779]\], which is an acronym for Systolic blood pressure, Multilobar infiltrates, Albumin, Respiratory rate, Tachycardia, Confusion, Oxygen, and pH, evaluates pneumonia severity and predicts the need for intensive respiratory or vasopressor support (IRVS) in CAP. The pretreatment SMART-COP score was 5, placing him in the high-risk group, and signifying a 1 in 3 chance of needing IRVS. Following PBMT, the SMART-COP decreased to 2, implying minimal risk for needing IRVS.

The Brescia-COVID Respiratory Severity Scale \[[@b26-amjcaserep-21-e926779]\] is a stepwise algorithm for managing patients with confirmed COVID-19. Before treatment, the patient's score was 4 out of 4, which requires a trial of high-flow nasal cannula (HFNC), reassessment, and intubation if the score remains \>2. Following PBMT, the patient's Brescia-COVID score was 0, which simply requires patient monitoring.

The CAP tool score \[[@b27-amjcaserep-21-e926779]\] is a short and sensitive questionnaire evaluating changes in respiratory symptoms and well-being during the treatment of community-acquired pneumonia. Scores \<75% indicate symptomatic distress. The patient's pretreatment CAP score was 36.68% and increased to 82.84% after treatment. His CAP Respiratory Score improved from 67.52%, before treatment to 87.17% at the time of discharge. The CAP Well-Being score increased from 0% before treatment to 73.07% after treatment. This patient demonstrated substantial improvement in all 3 measures of respiratory symptoms.

The Radiographic Assessment of Lung Edema (RALE) score \[[@b28-amjcaserep-21-e926779],[@b29-amjcaserep-21-e926779]\] evaluates lung edema on CXR in ARDS patients. To quantify the extent of infection, a severity score was calculated \[[@b29-amjcaserep-21-e926779]\]. A score of 0 to 4 was assigned to each lung depending on the percent lung consolidation or ground-glass opacity, with 0 signifying no lung involvement, 1 indicating \<25% lung involvement, 2 indicating 25--50% lung involvement, 3 indicating 50--75% lung involvement, and 4 indicating \>75% involvement. The scores for each lung were added together to produce the final severity score \[[@b29-amjcaserep-21-e926779]\]. The RALE score was 8 (\>75% involvement of both lungs) and improved to 5 upon treatment completion ([Figure 3](#f3-amjcaserep-21-e926779){ref-type="fig"}).

His white blood cell count decreased from 10.7 to 6.5 and his C-reactive protein decreased from 15.1 to 1.23 after treatment. The oxygen requirement before treatment was 2--4 L/min with an oxygen saturation (SpO~2~) of 93--94%. The oxygen requirement after treatment improved to 1 L/min with an SpO~2~ of 97--100% at the time of discharge.

Discussion
==========

This case report showed that 4 daily sessions of adjunct PBMT were beneficial in a patient with severe COVID-19 symptoms. The patient's positive response to treatment was supported by radiological findings, pulmonary severity scores, oxygen requirements, blood and inflammatory markers, and patient questionnaires. On follow-up, his clinical recovery in total was 3 weeks, whereas the median time for COVID-19 is typically 6--8 weeks \[[@b30-amjcaserep-21-e926779]\].

The therapeutic effects of PBMT on pneumonia are thought to occur via local and systemic effects that reduce inflammatory cytokines, cellular infiltrates, edema and fibrosis, and increase anti-inflammatory cytokines and processes, and promote healing. Local PBMT affects the entire body when photoproducts are distributed via the vasculature to reach distant targets. Activated photoproducts lead to alleviation of inflammation and immunomodulatory effects, and stimulate wound healing and tissue regeneration \[[@b4-amjcaserep-21-e926779]\]. Animal studies illustrate the potency of PBMT.

Transcutaneous PBMT in murine models for pulmonary fibrosis and ARDS significantly reduced pro-inflammatory cytokines, inflammatory cells, and collagen fiber deposition in lung parenchyma \[[@b14-amjcaserep-21-e926779]--[@b18-amjcaserep-21-e926779]\]. In contrast, the anti-inflammatory cytokine interleukin-10, serum monocytes, and lung macrophages were significantly increased following PBMT \[[@b15-amjcaserep-21-e926779],[@b17-amjcaserep-21-e926779]\]. The molecular basis of MLS laser anti-inflammatory effects has been demonstrated in murine and *in vitro* models \[[@b31-amjcaserep-21-e926779]--[@b33-amjcaserep-21-e926779]\]. In particular, it has been shown to inhibit inflammasome activation, inhibiting interleukin-1β and interleukin-18, whose downstream signaling induces the production of interleukin-6, interleukin-8, tumor necrosis factor α (TNF-α), and interferon-γ, which are implicated in ARDS caused by COVID-19 infection \[[@b14-amjcaserep-21-e926779]--[@b18-amjcaserep-21-e926779],[@b31-amjcaserep-21-e926779]--[@b33-amjcaserep-21-e926779]\].

Human trials have shown local and systemic effects of PBMT when applied to quadriceps muscle in patients with chronic obstructive pulmonary disease \[[@b10-amjcaserep-21-e926779]\]. Beneficial effects extended beyond improved muscular performance, to statistically significant reductions in dyspnea and fatigue \[[@b10-amjcaserep-21-e926779]\]. Our patient also reported subjective feelings of improved respiratory function and strength.

Our patient was only placed in the prone position for the duration of laser treatment. Treatments lasted exactly 28 min for each of the 4 days. Physiological evidence and clinical trial data support the use of prone position ventilation in selected patients with moderate-to-severe ARDS. For patients to benefit, the use of long prone positioning sessions of 12 h to 18 h per session are necessary \[[@b34-amjcaserep-21-e926779],[@b35-amjcaserep-21-e926779]\]. An increase in SpO~2~ from 94% to 100% occurred within the first 5 min of treatment, and the patient maintained good saturation thereafter. This finding shows the rapid effect of PBMT treatment on oxygen saturation. It is unlikely that prone positioning alone was the reason for improved oxygenation, given the minimal time in that position.

A strength of this case report is that we collected patient symptom data before and after treatment. All 4 pulmonary scoring tools and the 3 patient questionnaires demonstrated the benefit of treatment. To the best of our knowledge, this was the first time that PBMT was used as adjunctive treatment for pneumonia in a COVID-19 patient. Irradiation over the posterior projection of the lungs, using the scanning method, has no risk of contamination since the scanning laser does not physically touch the patient. A deficiency of our study is the lack of inflammatory markers and blood tests. Future studies should include measurements before and after treatment of interleukin-6, interleukin-10, TNF-α, as well as additional inflammatory markers. A limitation of this case report is that this is a single patient and we were unable to carry out any statistical analysis.

Conclusions
===========

This report has presented a patient with severe COVID-19 pneumonia associated with ARDS who was given supportive treatment with PBMT. Based on this case report, as well as clinical experience of PBMT in respiratory tract diseases in humans, we consider PBMT to be a feasible adjunct modality for the treatment of COVID-19. There is published experimental work demonstrating the anti-inflammatory effect of PBMT on lung tissue. We suggest that the use of adjunct PBMT in the early stages of severe ARDS seen in COVID-19 patients can enhance healing and reduce the need for prolonged ventilator support and ICU stay. The urgent current medical situation calls for PMBT pilot studies and clinical trials to evaluate its effect on COVID-19 pneumonia. This patient is part of an ongoing investigational randomized controlled trial.

![Orientation of the laser beams during laser treatment while in the prone position. The apex of the lung lies above the first rib. The lungs extend from the C7 to T10 vertebra, which is also from the apex of the lung to the inferior border. Laser parameters with both diodes operating synchronously and simultaneously, and the propagation axes are coincident. 1) 808 nm (GaAlAs) diode: Peak Power: 3 W, Laser Mode: Pulsed, Frequency: 1500 Hz, Pulse Duration: 333 μs, Scanning Area: 25×10=250 cm^2^, Dose: 7.2 J/cm^2^; 2) 905 nm (GaAs) diode: Peak Power: 75 W×3, Laser Mode: Pulsed, Frequency: 1500 Hz, Pulse Duration: 100 ns, Area: 25×10=250 cm^2^, Dose: 113.4 mJ/cm^2^; Total Energy: 3600 J. Treatment Time: (28 minutes), 14 minutes each lung, Sessions: Once daily for 4 days. Therapeutic Protocol: PBMT-COVID-19 By Dr. S. Mokmeli.](amjcaserep-21-e926779-g001){#f1-amjcaserep-21-e926779}

![Laser scanner configuration while the patient is in the prone position with scapular protraction. The laser scanner was adjusted 20 cm above the skin as per manufacturer's guidelines. The patient is shown here with his hands under his head for maximum scapular protraction. The red light is the laser machine's guide beam on the skin. Infrared lasers with wavelengths of 808 and 905 nm are not visible to human eyes. The 2 sources are coupled in a single system in the MLS laser system.](amjcaserep-21-e926779-g002){#f2-amjcaserep-21-e926779}

![Radiographic Assessment of Lung Edema (RALE) by CXR showed reduced ground-glass opacities and consolidation following PBMT. Lung radiographic score is dependent on extent of involvement based on consolidation or ground-glass opacities for each lung. Total score is the sum of both lungs. Scores classification: 0 -- no involvement; 1 -- \<25% of lung involved; 2 -- 25--50% of lung involved; 3 -- 50--75% of lung involved; 4 -- \>75% of lung involved. RALE score before laser therapy (04-27-2020)=8. Laser therapy started on (04-29-2020). RALE score after laser therapy (05-03-2020)=5.](amjcaserep-21-e926779-g003){#f3-amjcaserep-21-e926779}

###### 

Laser parameters for COVID-19 pneumonia patients.

  ------------------------------------------------------------------------------------------------------------
                           **808 nm (GaAlAs) diode**                **905 nm (GaAs) diode**
  ------------------------ ---------------------------------------- ------------------------------------------
  Mode of radiation        Pulsed                                   Pulsed

  Frequency                1500 Hz, (Duty Cycle 50%) (1 Hz÷2 kHz)   1500 Hz (90 kHz Modulated at 1 Hz÷2 kHz)

  Pulse duration           333 μs (500 ms÷250 μs)                   100 ns

  Peak power               3 W                                      75W×3

  Average power            1.5 W                                    11.25×3=33.75 mW

  Spot size                19.625 cm^2^                             

  Area                     On each lung\                            
                           25×10=250 cm^2^                          

  Dose                     7.1--7.2 J/cm^2^                         

  Distance from the skin   20 cm                                    

  Treatment time           14 minutes each lung                     

  Total energy             3600 J\                                  
                           1794.24 each lung                        

  Total time               28 minutes                               

  Sessions                 Once daily for 4 days                    
  ------------------------------------------------------------------------------------------------------------

The table explains the technical parameters for the dosage of laser energy and treatment time used in this case report. GaAlAs -- Gallium Aluminum Arsenide Diode; GaAs -- Gallium Arsenide Diode. The two diodes are part of a single laser system, the Multiwave Locked System (MLS). For patients with dark skin color, there is a pigment adjustment selection button on the laser console. When the pigment selection is activated, laser intensity is reduced by 50% and the software automatically recalculates the required dose.

###### 

Evaluation criteria before and after photobiomodulation therapy in a COVID-19 patient.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Parameters**     **Before treatment**   **After treatment**   **Normal range or evaluation criteria**
  ------------------ ---------------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PSI                Class V (142)          Class II (67)         Risk Class (Points): Disposition\
                                                                  Class I (\<50): Outpatient\
                                                                  Class II (51--70): Outpatient\
                                                                  Class III (71--90): Outpatient/brief Inpatient\
                                                                  Class IV (91--130): Inpatient\
                                                                  Class V (\>130): Inpatient

  SMART-COP          5                      2                     0 points: Very low risk of needing IRVS\
                                                                  1 point: Low risk (1 in 20) of needing IRVS\
                                                                  2 points: Moderate risk (1 in 10) of needing IRVS\
                                                                  3 points: High risk (1 in 6) of needing IRVS\
                                                                  ≥4 points: High risk (1 in 3) of needing IRVS; Consider ICU admission

  Brescia-COVID      4                      0                     0 -- monitor\
                                                                  1 -- add O~2~ and monitor\
                                                                  2 -- CXR, ABG, O~2~ therapy, monitor\
                                                                  \>2 -- HFNC and reassess. If still \>2, intubate.

  CAP total          36.68                  82.82                 Calculated based on (CAP) score questionnaire: 75--100%

  CAP respiratory    67.52                  87.17                 75--100%

  CAP well-being     0.0                    73.07                 75--100%

  RALE               8                      5                     Lungs score dependent on extent of involvement based on consolidation or ground-glass opacities for each lung, total score is the sum of the score of the lungs: 0 -- no involvement; 1 -- \<25% of lung involved; 2 -- 25--50% of lung involved; 3 -- 50--75% of lung involved; 4 -- \>75% of lung involved.

  WBC                10.7                   6.5                   4.5--11

  CRP                15.1                   1.23                  3 mg/mL

  O~2~ Requirement   2--3 L/min             1 L/min               0 L/min

  SpO~2~             93--94%                100%                  ≥94%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSI -- Pneumonia Severity Index; SMART-COP -- Systolic blood pressure, Multilobar infiltrates, Albumin, Respiratory rate, Tachycardia, Confusion, Oxygen, and pH; CAP -- Community-Acquired Pneumonia; RALE -- Radiographic Assessment of Lung Edema; SpO~2~ -- Oxygen saturation; WBC -- White Blood Cells; CRP -- C-Reactive Protein; IRVS -- Intensive Respiratory or Vasopressor Support; CXR -- Chest x-ray; ABG -- Arterial Blood Gas; HFNC -- High-Flow Nasal Cannula.
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